StockNews.com initiated coverage on shares of Forward Pharma A/S (NASDAQ:FWP – Get Rating) in a research report issued to clients and investors on Monday. The firm set a “sell” rating on the biotechnology company’s stock.
Shares of Forward Pharma A/S stock opened at $5.35 on Monday. The business’s 50 day simple moving average is $5.60 and its two-hundred day simple moving average is $5.70. Forward Pharma A/S has a one year low of $4.85 and a one year high of $20.31.
Several institutional investors and hedge funds have recently bought and sold shares of FWP. Morgan Stanley boosted its position in shares of Forward Pharma A/S by 1.2% during the second quarter. Morgan Stanley now owns 181,799 shares of the biotechnology company’s stock valued at $1,563,000 after purchasing an additional 2,099 shares in the last quarter. Goldman Sachs Group Inc. bought a new stake in shares of Forward Pharma A/S during the third quarter valued at approximately $105,000. Renaissance Technologies LLC bought a new stake in shares of Forward Pharma A/S during the third quarter valued at approximately $597,000. Finally, Citadel Advisors LLC bought a new stake in shares of Forward Pharma A/S during the third quarter valued at approximately $141,000. 10.41% of the stock is currently owned by hedge funds and other institutional investors.
Forward Pharma A/S does not have significant operations. Previously, it operated as a biopharmaceutical company that focused on developing FP187 proprietary formulation of dimethyl fumarate for the treatment of inflammatory and neurological indications. Forward Pharma A/S was incorporated in 2005 and is headquartered in Copenhagen, Denmark.
- Get a free copy of the StockNews.com research report on Forward Pharma A/S (FWP)
- 3 Software Plays Showing Signs of Recovery
- It’s Time To PLAY With Dave & Buster’s
- Seagate Technology: Improved Fundamentals & Recovering Technicals
- It’s A Sweet Time To Buy The J.M. Smucker Co.
- Don’t Rush Out To Buy G-III Apparel
Receive News & Ratings for Forward Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Forward Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.